Month: January 2007
-
Abbott Laboratories is currently fighting antitrust allegations relating to two of its best-selling drugs: Norvir, a protease inhibitor used in AIDS treatment, and Hytrin, a drug used to treat enlarged prostate and hypertension. Last week the Wall Street Journal ran a cover story on the Norvir case entitled "Inside Abbott’s Tactics to Protect AIDS Drug." …
-
MedImmune v. Genentech et al., 549 U.S. ___ (2007) The U.S. Supreme Court handed down its highly anticipated decision in MedImmune v. Genentech today, holding by an 8-1 majority that a patent licensee is not required to terminate its license agreement before seeking a declaratory judgment that the subject patent is invalid, unenforceable, or not…
-
Law Seminars International will present its “Biotechnology 2007: Key Legal and Business Developments” conference January 28-29, 2007, in San Francisco. Speakers include outside and inside counsel, biotechnology industry executives, and financiers. The first day of the conference will focus on legal developments important to the biotechnology industry, while the second day will focus on business and financing issues. Specific…
-
Abbott Labs. v. Andrx Pharms. et al., No. 06-1101 (Fed. Cir. 2006) Abbott Labs is fending off multiple generic challenges to Biaxin XL (clarithromycin extended-release tablets), an antibiotic with annual sales of over $300 million in the United States. Companies that have filed ANDAs for generic versions of Biaxin XL include Ranbaxy, Teva, Andrx, Roxane,…
-
People in academia seem more interested lately in the activities of the pharmaceutical industry. Kyle Jensen, a Research Affiliate at the Harvard-MIT Division of Health Sciences & Technology, and C. Scott Hemphill, an Associate Professor of Law at Columbia, recently contacted me and let me know about their work. Dr. Jensen and his group analyzed…
-
American Conference Institute has announced that its 3rd National Conference on Life Sciences IP Due Diligence will take place in San Francisco on January 22-23, 2007. This event features leading IP practitioners and experienced in–house counsel from the West Coast who will address some of the unique challenges facing companies when conducting IP due diligence,…
Orange Book Blog 